@Article{,
AUTHOR = {Dean Elterman, Bruce Gao, Kevin C. Zorn, Naeem Bhojani, Bilal Chughtai},
TITLE = {How I Do It: Temporarily Implanted Nitinol Device (iTind)},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {28},
YEAR = {2021},
NUMBER = {4},
PAGES = {10788--10793},
URL = {http://www.techscience.com/CJU/v28n4/60287},
ISSN = {1488-5581},
ABSTRACT = {Benignprostatichyperplasiaisacommonandprogressive diseaseaffectingagingmenwhichhasasignifcantimpact on quality of life.  The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporaryprostaticurethraldevicewhichcanbedeployed using standard fexible cystoscopy without sedation or generalanesthesia.Thedeviceisleftin-situfor5to7days and is then entirely removed in the offce, using an open-ended silicone catheter.  Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes.  Readers will familiarize themselves withiTind,signifcanthistoricalstudiesandthetechnique for deploying iTind using a fexible cystoscope in the offce setting.  },
DOI = {}
}